Delphinus Medical Technologies key facts
as of Oct 2026- Developer of an ultrasound system designed to transform the early detection of breast cancer.
- Delphinus Medical Technologies is valued at approximately $210.0M as of Oct 2026, set at its later-stage round, Aug 2023; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $161.4M across 5 recorded rounds; the latest was Debt ($27.6M) in Mar 2024.
- Notable investors include Invest Detroit Ventures, Arboretum Ventures, Beringea, University of Michigan Endowment, InvestMichigan! Program — 14 tracked in total.
- Delphinus Medical Technologies has filed 9 Form Ds with the SEC since 2010, most recently Apr 2025 ($27.6M sold to 8 investors).
- Status: Privately Held (backing).
Valued at $210.0M at its later-stage round, Aug 2023. Nothing has traded since.
- ·The complete investor list: 14 names
- ·Watch Delphinus Medical Technologies: the Monday email on marks, rounds and moves
Delphinus Medical Technologies funding rounds
5 roundsWho backs Delphinus Medical Technologies
14+Membership and data by Private Market View
Delphinus Medical Technologies valuation
Delphinus Medical Technologies was valued at $210 million at its later-stage round in Aug 2023. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has Delphinus Medical Technologies raised?
Delphinus Medical Technologies has raised $161 million across 5 recorded rounds since 2015. The largest was an $8.2 million early-stage round in Apr 2017; the most recent was a $27.6 million debt round in Mar 2024.
Delphinus Medical Technologies has filed 9 Form Ds with the SEC since 2010, most recently in Apr 2025 ($27.6 million sold to 8 investors).
Delphinus Medical Technologies investors
14 investors are on record for Delphinus Medical Technologies, including Invest Detroit Ventures, Arboretum Ventures, Beringea and University of Michigan Endowment. The debt round in Mar 2024 drew 8 investors.
About Delphinus Medical Technologies
Developer of an ultrasound system designed to transform the early detection of breast cancer. The company's system differentiates benign from malignant masses in breast cancer cases with the use of sound and water and utilizes a ring transducer to transmit and receive ultrasound signals, enabling medical professionals to better define and diagnose breast cancers and provide a better patient experience for women regardless of age, without concern of radiation or discomfort.
- Sector
- Healthcare
- HQ
- Novi, MI, United States
- Founded
- 2010
- Employees
- 51
- Website
- delphinusmt.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.